ABT-737

For research use only. Not for use in humans.

目录号：S1002

CAS No. 852808-04-9

ABT-737是一种BH3模拟抑制剂，作用于Bcl-xL，Bcl-2和Bcl-w，无细胞试验中EC50分别为78.7 nM，30.3 nM和197.8 nM；但对Mcl-1， Bcl-B及Bfl-1没有抑制作用。ABT-737可诱导线粒体通路的凋亡和线粒体自噬。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 3144.65	现货
5mg	RMB 972.14	现货
50mg	RMB 4659.22	现货
100mg	RMB 7964.03	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的ABT-737发表文献313篇：

Cell, 2018, 175(2):429-441

PubMed: 30245008 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):435-449

PubMed: 29533784 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Nat Methods, 2017, 14(9):891-896

PubMed: 28737741 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Nat Med, 2013, 19(11):1478-88

PubMed: 24141421 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

J Infect, 2021, S0163-4453(21)00200-0

PubMed: 33892015 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(10)5405

PubMed: 34065600 ( click the link to review the publication )

Adv Biol Regul, 2021, S2212-4926(20)30091-9

PubMed: 33451973 ( click the link to review the publication )

Commun Biol, 2021, 4(1):20

PubMed: 33398046 ( click the link to review the publication )

ACS Nano, 2020, 14(3):3378-3388

PubMed: 32083466 ( click the link to review the publication )

Sci Adv, 2020, 6(47)eabc3465

PubMed: 33208362 ( click the link to review the publication )

Nat Commun, 2020, 11(1):259

PubMed: 31937780 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

EMBO J, 2020, e105071

PubMed: 32840892 ( click the link to review the publication )

Cancer Res, 2020, 10.1158/0008-5472.CAN-19-1784

PubMed: 32005716 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(2) pii: E406

PubMed: 32050632 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0756

PubMed: 33334730 ( click the link to review the publication )

Development, 2020, 147(22)dev194555

PubMed: 33028610 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.510.2019

PubMed: 32371581 ( click the link to review the publication )

Allergy Asthma Immunol Res, 2020, 12(4):608-625

PubMed: 32400128 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )
Front Mol Biosci, 2020, 7:566291

PubMed: 33425984 ( click the link to review the publication )

Sci Rep, 2020, 20;10(1):687

PubMed: 31959760 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:405

PubMed: 32863764 ( click the link to review the publication )

Biomed Pharmacother, 2020, 126:110040

PubMed: 32145585 ( click the link to review the publication )

Ann Transl Med, 2020, 8(6):364

PubMed: 32355808 ( click the link to review the publication )

Eur J Pharm Sci, 2020, 142:105105

PubMed: 31669390 ( click the link to review the publication )

Platelets, 2020, 10.1080/09537104.2020.1724276

PubMed: 32079453 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038

PubMed: 32015503 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002

PubMed: 32061152 ( click the link to review the publication )

Cell Rep, 2020, 32(1):107845

PubMed: 32640215 ( click the link to review the publication )

Life Sci Alliance, 2020, 28;3(6) pii: e202000735

PubMed: 32345661 ( click the link to review the publication )

Transfusion, 2020, 60(4):806-814

PubMed: 32159862 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0234103

PubMed: 32645016 ( click the link to review the publication )

Infect Immun, 2020, 10.1128/IAI.00851-19

PubMed: 32179584 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

STAR Protoc, 2020, 1(1)100034

PubMed: 32793892 ( click the link to review the publication )

Cell Death Dis, 2020, 11(1):8

PubMed: 31907357 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5770

PubMed: 31852899 ( click the link to review the publication )

EMBO J, 2019, 15;38(10):e101638

PubMed: 30902848 ( click the link to review the publication )

EMBO J, 2019, 38(11)

PubMed: 30979778 ( click the link to review the publication )

Dev Cell, 2019, 51(2):277-291

PubMed: 31564612 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2339-2351

PubMed: 30862722 ( click the link to review the publication )

Cell Rep, 2019, 27(12):3657-3671

PubMed: 31216482 ( click the link to review the publication )
Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Elife, 2019, 8e38730

PubMed: 31042147 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31540244 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31810230 ( click the link to review the publication )

Cell Death Dis, 2019, 10(2):121

PubMed: 30741926 ( click the link to review the publication )

J Cancer, 2019, 10(6):1466-1478

PubMed: 31031856 ( click the link to review the publication )

Thromb Haemost, 2019, 19(10):1665-1674

PubMed: 31493778 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:5820415

PubMed: 31885804 ( click the link to review the publication )

Eur J Immunol, 2019, 10.1002/eji.201948254

PubMed: 31411729 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(4):419-429

PubMed: 31467029 ( click the link to review the publication )

Biochem J, 2019, 476(9):1335-1357

PubMed: 30992316 ( click the link to review the publication )

Phytomedicine, 2019, 64:153068

PubMed: 31419729 ( click the link to review the publication )

Phytomedicine, 2019, 52:147-156

PubMed: 30599894 ( click the link to review the publication )

Life Sci, 2019, 232:116561

PubMed: 31247208 ( click the link to review the publication )

Chem Biol Interact, 2019, 309:108723

PubMed: 31228469 ( click the link to review the publication )

J Bone Oncol, 2019, 19:100268

PubMed: 31832331 ( click the link to review the publication )

J Bone Oncol, 2019, 15:100222

PubMed: 30766792 ( click the link to review the publication )

PLoS One, 2019, 14(12):e0225977

PubMed: 31826021 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:897-906

PubMed: 30774376 ( click the link to review the publication )

Platelets, 2019, 30(1):75-80

PubMed: 29125379 ( click the link to review the publication )

Oncotarget, 2019, 10(58):6219-6233

PubMed: 31692812 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 200(1):84-97

PubMed: 30649895 ( click the link to review the publication )
Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5435

PubMed: 30575733 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(21):5458-5470

PubMed: 30021909 ( click the link to review the publication )

Cell Death Differ, 2018, 25(4):784-796

PubMed: 29229994 ( click the link to review the publication )

Oncogene, 2018, 37(39):5325-5339

PubMed: 29858601 ( click the link to review the publication )

Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(14):2663-2680

PubMed: 29396625 ( click the link to review the publication )

Cancers (Basel), 2018, 10(11)E439

PubMed: 30441794 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):994

PubMed: 30250198 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):199

PubMed: 29415991 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(3):1123-1138

PubMed: 30041196 ( click the link to review the publication )

Eur J Med Chem, 2018, 159:357-380

PubMed: 30308410 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(3):522-531

PubMed: 29278689 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(6):935-946

PubMed: 29545477 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Sci Rep, 2018, 8(1):15752

PubMed: 30361682 ( click the link to review the publication )

Int J Oncol, 2018, 53(3):1055-1068

PubMed: 30015875 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(6):465-474

PubMed: 29394130 ( click the link to review the publication )

Phytother Res, 2018, 32(6):1126-1134

PubMed: 29464855 ( click the link to review the publication )

Thromb Res, 2018, 171:22-30

PubMed: 30240944 ( click the link to review the publication )

Environ Mol Mutagen, 2018, 59(1):49-59

PubMed: 28843007 ( click the link to review the publication )
Ann Surg Treat Res, 2018, 95(5):240-248

PubMed: 30402442 ( click the link to review the publication )

Oncotarget, 2018, 9(28):20075-20088

PubMed: 29732004 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Oncotarget, 2018, 9(42):26834-26851

PubMed: 29928488 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Biomaterials, 2017, 144:73-83

PubMed: 28823845 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Cell Death Differ, 2017, 24(11):1963-1974

PubMed: 28777375 ( click the link to review the publication )

Elife, 2017, 6e22509

PubMed: 28425914 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 29148970 ( click the link to review the publication )

Oncogene, 2017, 36(15):2066-2073

PubMed: 27694901 ( click the link to review the publication )

Cancer Lett, 2017, 411:19-26

PubMed: 28987383 ( click the link to review the publication )

Sci Signal, 2017, 10(499)

PubMed: 28974650 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Eur J Immunol, 2017, 47(6):1009-1021

PubMed: 28493377 ( click the link to review the publication )

Biochem Pharmacol, 2017, 140:41-52

PubMed: 28595877 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15105-15120

PubMed: 28673964 ( click the link to review the publication )

Analyst, 2017, 142(23):4399-4404

PubMed: 29116264 ( click the link to review the publication )
Mol Cell Biol, 2017, 37(3)e00535-16

PubMed: 27821478 ( click the link to review the publication )

Clin Immunol, 2017, 181:32-42

PubMed: 28579554 ( click the link to review the publication )

Toxicol In Vitro, 2017, 42:38-46

PubMed: 28366708 ( click the link to review the publication )

Mol Cell Biochem, 2017, 429(1-2):91-102

PubMed: 28120212 ( click the link to review the publication )

Arch Oral Biol, 2017, 73:1-6

PubMed: 27632413 ( click the link to review the publication )

Oncol Lett, 2017, 14(1):903-908

PubMed: 28693250 ( click the link to review the publication )

Asia Pac J Clin Oncol, 2017, 13(2):e144-e152

PubMed: 26552712 ( click the link to review the publication )

Oncotarget, 2017, 8(65):108522-108533

PubMed: 29312548 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

J Allergy Clin Immunol, 2017, 140(2):418-430

PubMed: 28043871 ( click the link to review the publication )

Cell Death Dis, 2017, 8(6):e2898

PubMed: 28661475 ( click the link to review the publication )

Oncotarget, 2017, 8(43):74299-74311

PubMed: 29088786 ( click the link to review the publication )

Anat Rec (Hoboken), 2017, 300(2):326-339

PubMed: 27486855 ( click the link to review the publication )

Thromb Haemost, 2017, 117(2):311-324

PubMed: 27929199 ( click the link to review the publication )

Oncotarget, 2017, 8(29):46801-46817

PubMed: 27086916 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28692422 ( click the link to review the publication )

Oncotarget, 2017, 8(5):8670-8678

PubMed: 28055968 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(6):E980-E989

PubMed: 28049849 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):181-94

PubMed: 26619119 ( click the link to review the publication )

Nat Commun, 2016, 7:11190

PubMed: 27048913 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(5):1138-49

PubMed: 26467384 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1313-9

PubMed: 26759243 ( click the link to review the publication )
Br J Pharmacol, 2016, 173(3):471-83

PubMed: 26493374 ( click the link to review the publication )

Cell Death Dis, 2016, 7(8):e2342

PubMed: 27537525 ( click the link to review the publication )

Br J Cancer, 2016, 114(11):1219-26

PubMed: 27140314 ( click the link to review the publication )

Oncogenesis, 2016, 10.1038/oncsis.2016.33

PubMed: 27159675 ( click the link to review the publication )

J Virol, 2016, 90(5):2356-71

PubMed: 26676786 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(4):562-71

PubMed: 26704388 ( click the link to review the publication )

Lab Invest, 2016, 96(10):1128-37

PubMed: 27617402 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(6):1345-57

PubMed: 27429848 ( click the link to review the publication )

Cancer Cell Int, 2016, 16:27

PubMed: 27042160 ( click the link to review the publication )

J Immunother, 2016, 39(3):117-26

PubMed: 26938945 ( click the link to review the publication )

Cell Cycle, 2016, 15(12):1531-7

PubMed: 25483065 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 477(4):607-13

PubMed: 27343560 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):143-148

PubMed: 27449608 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Exp Ther Med, 2016, 11(2):669-673

PubMed: 26893664 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83208-83222

PubMed: 27825124 ( click the link to review the publication )

Sci Rep, 2016, 6:21264

PubMed: 26887909 ( click the link to review the publication )

Oncotarget, 2016, 7(3):3520-32

PubMed: 26657288 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10839-49

PubMed: 26880588 ( click the link to review the publication )

Oncotarget, 2016, 7(51):85492-85501

PubMed: 27863431 ( click the link to review the publication )

Oncotarget, 2016, 7(24):35989-36001

PubMed: 27056884 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

Oncotarget, 2016, 7(48):79637-79653

PubMed: 27793034 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84594-84607

PubMed: 27829238 ( click the link to review the publication )
Oncotarget, 2016, 7(47):77815-77824

PubMed: 27780925 ( click the link to review the publication )

Blood, 2015, 24;126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Autophagy, 2015, 11(3):452-9

PubMed: 25715028 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(17):3995-4003

PubMed: 26015514 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(6):E536-45

PubMed: 25624498 ( click the link to review the publication )

EMBO Rep, 2015, 16(5):618-27

PubMed: 25739811 ( click the link to review the publication )

Cancer Res, 2015, 75(24):5318-28

PubMed: 26670562 ( click the link to review the publication )

Cancer Res, 2015,

PubMed: 25432173 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.8

PubMed: 25698446 ( click the link to review the publication )

J Med Chem, 2015, 58(4):1644-68

PubMed: 25585174 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1989

PubMed: 26583329 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: 25308513 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(19):12290-9

PubMed: 25829495 ( click the link to review the publication )

J Biol Chem, 2015, 290(34):20841-55

PubMed: 26124276 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:34

PubMed: 25852302 ( click the link to review the publication )

Neurogastroenterol Motil, 2015, 10.1111/nmo.12521

PubMed: 25690069 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):667-76

PubMed: 25434832 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: 25596561 ( click the link to review the publication )

Exp Cell Res, 2015, 335(1):62-7

PubMed: 26024774 ( click the link to review the publication )

Exp Cell Res, 2015, 10.1016/j.yexcr.2015.04.016

PubMed: 25936772 ( click the link to review the publication )

BMC Cancer, 2015, 15:919

PubMed: 26585594 ( click the link to review the publication )
Chembiochem, 2015, 16(5):757-65

PubMed: 25711460 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143685

PubMed: 26606677 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 464(1):286-91

PubMed: 26116776 ( click the link to review the publication )

Exp Hematol, 2015, 43(3):180-190.e6

PubMed: 25461257 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 10.1016/j.mrfmmm.2015.04.005

PubMed: ( click the link to review the publication )

Cell Biochem Funct, 2015, 33(5):334-40

PubMed: 26178811 ( click the link to review the publication )

Anticancer Res, 2015, 35(3):1803-8

PubMed: 25750346 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

Oncotarget, 2015, 6(26):22624-40

PubMed: 26265439 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36338-53

PubMed: 26462148 ( click the link to review the publication )

Oncotarget, 2015, 6(8):5582-96

PubMed: 25714024 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Oncotarget, 2015, 6(1):409-26

PubMed: 25565667 ( click the link to review the publication )

Oncotarget, 2015, 6(34):35667-83

PubMed: 26447615 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Hepatol Res, 2015, 45(9):1023-1033

PubMed: 25297967 ( click the link to review the publication )

Nat Commun, 2014, 5:5637

PubMed: 25472497 ( click the link to review the publication )

Autophagy, 2014, 10(10):1776-86

PubMed: 25126729 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5446-55

PubMed: 25208882 ( click the link to review the publication )

Leukemia, 2014, 28(10):1960-8

PubMed: 24577530 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Biomaterials, 2014, 16(2):R41

PubMed: 24745479 ( click the link to review the publication )

Cell Death Differ, 2014, 21(7):1170-7

PubMed: 24682005 ( click the link to review the publication )

Cell Death Differ, 2014, 10.1038/cdd.2014.158

PubMed: 25301069 ( click the link to review the publication )
Cancer Lett, 2014, 10.1016/j.canlet.2014.09.024

PubMed: 25304383 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Sci Signal, 2014, 7(357):ra122

PubMed: 25538080 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1514

PubMed: 25375379 ( click the link to review the publication )

Biomaterials Science, 2014, 10.1039/C4BM00072B

PubMed: ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1275

PubMed: 24901046 ( click the link to review the publication )

Acta Neuropathol Commun, 2014, 10.1186/2051-5960-2-57

PubMed: 24887326 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-13-0998

PubMed: 24739394 ( click the link to review the publication )

Mol Cancer Res, 2014, 13(12):3332-42

PubMed: 25154561 ( click the link to review the publication )

Mol Cancer Res, 2014, (4):550-9

PubMed: 24469836 ( click the link to review the publication )

J Immunol, 2014, 193(10):4914-23

PubMed: 25288570 ( click the link to review the publication )

Bone, 2014, 67:166-74

PubMed: 25016096 ( click the link to review the publication )

J Biol Chem, 2014, 289(22):15495-15506

PubMed: 24739390 ( click the link to review the publication )

J Immunother, 2014, 37(1):8-15

PubMed: 24316551 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(11):20500-17

PubMed: 25387078 ( click the link to review the publication )

Int J Cardiol, 2014, 176(3):923-9

PubMed: 25194861 ( click the link to review the publication )

Int J Hyperthermia, 2014, 30(7):502-12

PubMed: 25354679 ( click the link to review the publication )

Cell Cycle, 2014, 10.4161/15384101.2014.973321

PubMed: ( click the link to review the publication )

Thromb Res, 2014, 134(6):1311-5

PubMed: 25288466 ( click the link to review the publication )

Thromb Res, 2014, 133(1):73-9

PubMed: 24268298 ( click the link to review the publication )

PLoS One, 2014, 9(9):e103015

PubMed: 25181509 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84388

PubMed: 24427286 ( click the link to review the publication )
PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105049

PubMed: 25126950 ( click the link to review the publication )

PLoS One, 2014, 9(3):e91782

PubMed: 24626299 ( click the link to review the publication )

PLoS One, 2014, 9(5):e96733

PubMed: 24824755 ( click the link to review the publication )

Leuk Lymphoma, 2014, 5:1-12

PubMed: 25373508 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:306718

PubMed: ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(11):4321-6

PubMed: 23447565 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1532-45

PubMed: 23933817 ( click the link to review the publication )

Mol Cancer, 2013, 12(1):42

PubMed: 23680104 ( click the link to review the publication )

Int J Cancer, 2013, 133(8):1813-24

PubMed: 23580240 ( click the link to review the publication )

J Neurosci, 2013, 33(46):18098-108

PubMed: 24227720 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e702

PubMed: 23828565 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e931

PubMed: 24263105 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e762

PubMed: 23928701 ( click the link to review the publication )

Br J Cancer, 2013, 108(9):1870-8

PubMed: 23558901 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e690

PubMed: 23807219 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e801

PubMed: 24030153 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Br J Haematol, 2013, 163(3):377-84

PubMed: 24033315 ( click the link to review the publication )

Br J Haematol, 2013, 161(2):245-54

PubMed: 23398569 ( click the link to review the publication )

Stem Cells Transl Med, 2013, 2(9):690-702

PubMed: 23934910 ( click the link to review the publication )

Cancer Sci, 2013, 104(6):732-9

PubMed: 23421409 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(2):109-21

PubMed: 23233484 ( click the link to review the publication )
Cancer Gene Ther, 2013, 20(7):386-93

PubMed: 23788110 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):6826-34

PubMed: 23329846 ( click the link to review the publication )

Apoptosis, 2013, 18(11):1403-15

PubMed: 23760752 ( click the link to review the publication )

Biomed Pharmacother, 2013, 67(7):583-91

PubMed: 23706691 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 274(2):319-27

PubMed: 24321340 ( click the link to review the publication )

Int J Biochem Cell Biol, 2013, 45(5):944-51

PubMed: 23395630 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63232

PubMed: 23658815 ( click the link to review the publication )

PLoS One, 2013, 8(11):e78570

PubMed: 24223823 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 437(4):565-72

PubMed: 23850692 ( click the link to review the publication )

Leuk Lymphoma, 2013, 54(2):372-80

PubMed: 22830613 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Basic Clin Pharmacol Toxicol, 2013, 113(3):145-51

PubMed: 23557083 ( click the link to review the publication )

J Ovarian Res, 2013, 6(1):72

PubMed: 24103422 ( click the link to review the publication )

Phys Biol, 2013, 10(3):035002

PubMed: 23735516 ( click the link to review the publication )

Cytometry A, 2013, 83(2):227-34

PubMed: 23165976 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 24334291 ( click the link to review the publication )

Blood, 2012, 120(19):3978-85

PubMed: 22927247 ( click the link to review the publication )

Mol Cell, 2012, 46(5):573-83

PubMed: 22560721 ( click the link to review the publication )

J Clin Invest, 2012, 122(6):2018-31

PubMed: 22622039 ( click the link to review the publication )

EMBO J, 2012, 31(10):2322-35

PubMed: 22510886 ( click the link to review the publication )

Oncogene, 2012, 31(26):3177-89

PubMed: 22056880 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(3):R96

PubMed: 22703841 ( click the link to review the publication )

Anal Chem, 2012, 84(11):4703-10

PubMed: 22533353 ( click the link to review the publication )

Br J Haematol, 2012, 159(5):565-71

PubMed: 23025479 ( click the link to review the publication )
Mol Cancer Res, 2012, 10(3):347-59

PubMed: 22241218 ( click the link to review the publication )

J Biol Chem, 2012, 287(25):21357-70

PubMed: 22553204 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17682-92

PubMed: 22433870 ( click the link to review the publication )

Mol Endocrinol, 2012, 26(9):1508-20

PubMed: 22771494 ( click the link to review the publication )

Phytother Res, 2012, 27(6):835-40

PubMed: 22899281 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

PLoS One, 2012, 7(8):e43158

PubMed: 22912816 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52333

PubMed: 23284992 ( click the link to review the publication )

J Pharmacol Sci, 2012, 119(4):330-40

PubMed: 22814102 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

J Clin Invest, 2011, 121(3):1053-63

PubMed: 21317538 ( click the link to review the publication )

Leukemia, 2011, 25(11):1728-38

PubMed: 21701487 ( click the link to review the publication )

Neuro Oncol, 2011, 13(12):1265-76

PubMed: 21880625 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

Oncogene, 2011, 30(37):3918-29

PubMed: 21460857 ( click the link to review the publication )

Am J Nephrol, 2011, 34(6):549-59

PubMed: 22123611 ( click the link to review the publication )

Cancer Chemoth Pharm, 2011, 67(3):557-67

PubMed: 20473610 ( click the link to review the publication )

PLoS One, 2011, 6(6):e20423

PubMed: 21674052 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24102

PubMed: 21949692 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Curr Pharmacogenomics Person Med, 2011, 9(3):184-190

PubMed: 22162984 ( click the link to review the publication )

Mol Cancer Ther, 2010, 19(20):5591-601

PubMed: 20587662 ( click the link to review the publication )

J Biol Chem, 2010, 285(26):19910-20

PubMed: 20421300 ( click the link to review the publication )

Apoptosis, 2010, 15(10):1256-69

PubMed: 20582477 ( click the link to review the publication )
Exp Hematol, 2010, 38(10):908-921

PubMed: 20540984 ( click the link to review the publication )

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述

特性

ABT-737是第一代抗凋亡BCL-2家族蛋白小分子抑制剂。

靶点

Bcl-2 ^[1] (Cell-free assay)	Bcl-xL ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)	Bcl-B ^[1] (Cell-free assay)
30.3 nM(EC50)	78.7 nM(EC50)	197.8 nM(EC50)	1.82 μM(EC50)

体外研究

ABT-737降低BCL-2/BAX异质二聚体,而诱导HL60细胞凋亡,但是对细胞周期分布没有抑制效果。ABT-737也诱导细胞色素C从线粒体中释放，促进BAX构象改变，BAX与凋亡相关。在白血病模型中，ABT-737按30 mg/kg处理，阻断53%白血病负荷，且使鼠寿命明显延长。ABT-737不会导致血细胞数和血清组成发生异常。^[1]通过使Mcl-1失活而使抵抗细胞（Hela和MCF-7）对ABT-737敏感。当Mcl-1无效时，ABT-737也导致BAX/BAK-依赖的细胞色素C释放。ABT-737延长携带BCL-2肿瘤的鼠寿命。^[2]ABT-737从BCL2’s BH3结合袋取代BIM,使BIM激活BAX,诱导线粒体透化作用,快速致死慢性淋巴细胞性白血病(CLL)细胞。^[3] Noxa正向调节增强H196细胞对ABT-737敏感性。ABT-737抑制多种SCLC细胞系，包括NCI-H889, NCI-H1963, NCI-H1417, NCI-H146等的增殖，并诱导细胞凋亡。最近研究显示，ABT-737作用于ATLL细胞，明显诱导HTLV-1感染的T细胞凋亡。ABT-737按100 mg/kg剂量作用于ATLL鼠模型显示出强抗癌活性。^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
OCI-Ly1	NF24R2xE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NU\kZpVlOjVyIH7NxsA>	M1jV[\|czKGh?	NW\ReJVwTE2VTx?=	M4rh[oNifXOnZDC5O{UhdG:\|czDv[kB3cWGkaXzpeJkhcW5iY3XscJMhfHKjboPm[YN1\WRid3n0bEBDS0x4IIPpVm5C	M1rpTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkW3Nlg5Lz5{Nk[1O\|I5QDxxYU6=
KG1a	MmHmR4VtdCCYaXHibYxqfHliQYPzZZk>	NGrhNY8xNTFyIN88US=>	M2Tz[VI1KGh?	NEnDbmJFVVOR	NWL1SHBYUUN3ME23MlY5KM7:TTyg[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MlLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NUK3NVIoRjJ4NUWyO\|EzRC:jPh?=
Kasumi-1	M3vTV2NmdGxiVnnhZoltcXS7IFHzd4F6	M4fiNVAuOTBizszN	NFrZdVMzPCCq	M2XHd2ROW09?	NYXne29iUUN3ME20Mlg4KM7:TTyg[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NGG2W4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW1NlcyOid-Mk[1OVI4OTJ:L3G+
KG1a	MV\BdI9xfG:\|aYOgRZN{[Xl?	MUiwMVExKM7:TR?=	MUiyOEBp	Ml\ySG1UVw>?	NFjMcY1qdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV3MkexNkc,OjZ3NUK3NVI9N2F-
Kasumi-1	M1y0bmFxd3C2b4Ppd{BCe3OjeR?=	M{jDSFAuOTBizszN	MVOyOEBp	MYTEUXNQ	MmjPbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NGe3cHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW1NlcyOid-Mk[1OVI4OTJ:L3G+
MC-3	MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXq1M\|ExNzJyIN88US=>	MUWyOEBp	M4W5NWROW09?	MlrjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NFry[JQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS0O\|YyPSd-Mk[0OFc3OTV:L3G+
HN22	NGq1NWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWWyXI92Oi53L{euOU8zOi53IN88US=>	MYCyOEBp	NGe1[3ZFVVOR	MlK0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M{DpclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NES3OlE2Lz5{NkS0O\|YyPTxxYU6=
MC-3	NYrWNHJvSXCxcITvd4l{KEG\|c3H5	MlvmOU8yOC9{MDFOwG0>	MoiyNlQhcA>?	MlnsSG1UVw>?	MWPpcoR2[2W\|IHPhd5Bie2VvbXXkbYF1\WRiYYDvdJRwe2m\|	Ml\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2NEe2NVUoRjJ4NES3OlE2RC:jPh?=
HN22	NI\vboxCeG:ydH;zbZMhSXO\|YYm=	MoHCNk42NzdwNT:yNk42KM7:TR?=	NYnOUXZ7OjRiaB?=	NWmx[3R3TE2VTx?=	MnrGbY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?=	MofCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2NEe2NVUoRjJ4NES3OlE2RC:jPh?=
MOLT-4	MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\wOooyOC13MECwJI5O	NXTsfHFuPzJiaB?=	NFj0[2xFVVOR	NILhfmRKSzVyPUCuNVk5KM7:TR?=	NWj1Wm1zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVI{OzJpPkK2N\|kzOzN{PD;hQi=>
RS4;11	MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1X2b\|ExNTVyMECgcm0>	NULnbZE5PzJiaB?=	NEja[ndFVVOR	M{jTdGlEPTB;MD6wNFIh\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7MkOzNkc,OjZ\|OUKzN\|I9N2F-
JURKAT	NXSwTZVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MomyNVAuPTByMDDuUS=>	MUS3NkBp	M2TZRWROW09?	MmfoTWM2OD14NjFOwG0>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7MkOzNkc,OjZ\|OUKzN\|I9N2F-
CEM R	NVnZ[XhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLPNVAuPTByMDDuUS=>	MlzEO\|IhcA>?	MYfEUXNQ	MYHJR\|UxRTVwNDFOwG0>	M2L1R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{myN\|MzLz5{NkO5NlM{OjxxYU6=
CEM S	M3raU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorONVAuPTByMDDuUS=>	M3v0dVczKGh?	NYqwUm5sTE2VTx?=	M2rzZWlEPTB;MUKuNUDPxE1?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7MkOzNkc,OjZ\|OUKzN\|I9N2F-
MOLT-4	MnHCRZBweHSxc3nzJGF{e2G7	NFPETZIyOC1zMECwJI5O	NWjQRVhROjRiaB?=	NITmR5pFVVOR	M3\DUYNifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x	NIjJTIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5NlM{Oid-Mk[zPVI{OzJ:L3G+
CEM S	M2qzemFxd3C2b4Ppd{BCe3OjeR?=	MmfENVAuOTByMDDuUS=>	MoLmNlQhcA>?	MoroSG1UVw>?	NF7kN5pk[XW\|ZYOgeIhmKGOuZXH2ZYdmKG:oIFLjcE0zKGGwZDD0bIUh\G:5boLl[5Vt[XSrb36gc4YhSmOuLYjMJIFv\CCPY3ytNS=>	Mnr1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUKzN\|IoRjJ4M{myN\|MzRC:jPh?=
JURKAT	NH;wTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU[xNFAuOTByMDDuUS=>	M1\2XVQ5KGh?	M3LsUmROW09?	MXrJR\|UxRTl3NdMxPU4{KG6P	NVPhNYZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xO\|IzPjlpPkK2NVczOjZ7PD;hQi=>
LOUCY	NHnVN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUSxNFAuOTByMDDuUS=>	M{PBVVQ5KGh?	NEDsSJlFVVOR	Mn7PTWM2OD1\|Mj64xtEyOC57IH7N	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF5MkK2PUc,OjZzN{KyOlk9N2F-
WM-115	MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NHXMc\|kyODEEoH7N	NH:xeXY4OiCq		M4frWoVvcGGwY3XzJIN2emO3bXnuMYlv\HWlZXSgZY51cS2\|dYL2bZZidMLi	Mo\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMU[3O\|YoRjJ4MUG2O\|c3RC:jPh?=
B16	NYTFVW5OS2WubDDWbYFjcWyrdImgRZN{[Xl?	MYWxNFDDqG6P	NXvoblZlPzJiaB?=		NXjwWXA3\W6qYX7j[ZMh[3W{Y4XtbY4ucW6mdXPl[EBidnSrLYP1dpZqfmGuwrC=	M4DJRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG2O\|c3Lz5{NkGxOlc4PjxxYU6=
HL-60	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX63NkBp		NX:1SolXUUN3MNMgQUAyOC55IH7N	M4S5UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MES1OlA6Lz5{NkC0OVYxQTxxYU6=
MOLM-13	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIjaPFk4OiCq		MWjJR\|UxyqB;IEK3Mlkhdk1?	M13xelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MES1OlA6Lz5{NkC0OVYxQTxxYU6=
OCI-AML3	M373emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV63NkBp		M3zoNWlEPTEEoE2gNVk2OCCwTR?=	NXfZO\|JKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFU3ODlpPkK2NFQ2PjB7PD;hQi=>
BCWM.1	NVTaR2hSSXCxcITvd4l{KEG\|c3H5	M1nP[lAuOS54IN88US=>	NF3NeFUzPCCq		NWLLTXhOcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MlXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OUOyPVAoRjJ3OEmzNlkxRC:jPh?=
MWCL-1	MonsRZBweHSxc3nzJGF{e2G7	M2XVPFAuOS54IN88US=>	M4fEUVI1KGh?		MVLpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NF25VoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi5N\|I6OCd-MkW4PVMzQTB:L3G+
MM.1s	NXXyUIdoSXCxcITvd4l{KEG\|c3H5	NXe4UVd6OC1zLk[g{txO	MY[yOEBp		NVT3XXpScW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MnPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OUOyPVAoRjJ3OEmzNlkxRC:jPh?=
HCT116	MYXGeY5kfGmxbjDBd5NigQ>?	Mn\uN{8yOCEQvF2=	NUjUW2x2OTMEoHlCpC=>	MV7EUXNQ	M{nNeIlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG\|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzNUCyPEc,OjV5MUWwNlg9N2F-
HCT116 BAX BAK1 DKO	MmHDSpVv[3Srb36gRZN{[Xl?	NUnsc4d5Oy9zMDFOwG0>	MWCxNuKhcMLi	NEDzdmRFVVOR	NEnzbnVqdmS3Y3XzJIEh\G:\|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4hVEN\|Qj3JTUBkd264ZYLzbY9vKGGwZDDTVXNVVTFiZHXndoFl[XSrb36=	M37hVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{G1NFI5Lz5{NUexOVAzQDxxYU6=
HCT116	MYjGeY5kfGmxbjDBd5NigQ>?	NYXYW4N3OTBizszN	MXyxNuKhcMLi	M3\OUWROW09?	NVm4O3c5cW6lcnXhd4V{KEeIUD3MR\|NDKHC3bnP0ZS=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzNUCyPEc,OjV5MUWwNlg9N2F-
HCT116 BAX BAK1 DKO	MXLGeY5kfGmxbjDBd5NigQ>?	MmLBNVAh\|ryP	Mmm3NVLDqGkEoB?=	NVvWTHUyTE2VTx?=	M4nDSYlv[3KnYYPld{BITlBvTFOzRkBxfW6ldHG=	NF7XVGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexOVAzQCd-MkW3NVUxOjh:L3G+
HCT116	NV3lS5g1SXW2b4DoZYd6KEG\|c3H5	MUKxNEDPxE1?	NVHDUWtSOTMEoHlCpC=>	M4XLT2ROW09?	NX\mbJBzcW6mdXPld{BiKGOxbYDs[ZRmKGG3dH;wbIFocWNicnXzdI9ve2V?	NWrjSJBkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVUxOjhpPkK1O\|E2ODJ6PD;hQi=>
HCT116 BAX BAK1 DKO	MoHJRZV1d3CqYXf5JGF{e2G7	MnzkNVAh\|ryP	NV6zO2FPOTMEoHlCpC=>	MmXFSG1UVw>?	NF:1PYFqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yC{ZYPwc45{\Q>?	NXW4PYtmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVUxOjhpPkK1O\|E2ODJ6PD;hQi=>
U937	MlL0RZBweHSxc3nzJGF{e2G7	NUKybJhOOC5zMkWtNkDPxE1?	MUOyOEBp		NFHjSVhmdmijbnPld{BFUEFxWD2xNU1qdmS3Y3XkJIFxd3C2b4Ppdy=>	NHTubJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexOFAzPCd-MkW3NVQxOjR:L3G+
U937	MYHBdI9xfG:\|aYOgRZN{[Xl?	Mnz5NE42KM7:TR?=	MkTQNlQhcA>?		NVXWNYVv\W6qYX7j[ZMh[2ynYY\h[4Uhd2ZiUFHSVEBidmRiY3HzdIF{\S1\|IHHzJJdmdGxiYYOgUo95[SCuZY\lcC=>	Mn7xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MUSwNlQoRjJ3N{G0NFI1RC:jPh?=
HL-60 AAA-Bcl-2	NU\Pcod6SXCxcITvd4l{KEG\|c3H5	NXyxe3FPOC13IN88US=>	MYi0PEBp		MXnJR\|UxRTBwOEeg{txu97zOaX7keYNmeyClZXzsJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NFrvW2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexNVQ3OCd-MkW3NVE1PjB:L3G+
HL-60 EEE-Bcl-2	M37PPWFxd3C2b4Ppd{BCe3OjeR?=	M2LoRlAuPSEQvF2=	Ml21OFghcA>?		M{XJO2lEPTB;NTFOwI3wxIxiaX7keYNmeyClZXzsJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzMUS2NEc,OjV5MUG0OlA9N2F-
U87	M1y0UGZ2dmO2aX;uJGF{e2G7	MVO1NEDPxE1?	NHHUPY4zPCCq		NWPEOGY3emWmdXPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsd{Bw\iCPTWCtNkwhVU2SLUG0JIFv\CCEY3ytNi=>	NIjme4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[2O\|Y3Oyd-MkW2Olc3PjN:L3G+
K562	NVO2OVViS2WubDDWbYFjcWyrdImgRZN{[Xl?	NUjSZ\|hlOS1zMDFOwG0>	M3nLR\|Q5KGh?	MV3EUXNQ	M1;CSmlEPTB;Mk[uO{DPxE1?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7NkW2NUc,OjV3OU[1OlE9N2F-
K562/Mcl -1-IRESBim	M{\s[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofTTWM2OD17LkOg{txO	MnnoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
K562/Bcl- 2-IRESBim	NUnuO3lbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3n0PWlEPTB;MD6zOUDPxE1?	NXrjd2lHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|U6ODBpPkK1OVM2QTByPD;hQi=>
Jurkat	NWCwU4dET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXkb2JyUUN3ME2wMlY3KM7:TR?=	NHHDVpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzOVkxOCd-MkW1N\|U6ODB:L3G+
JurkatΔBak	M{PFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;VXWlEPTB-NUCg{txO	MnzhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
HL60/VCR	NH;QW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRjFyMDFOwG0>	NHT6dJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzOVkxOCd-MkW1N\|U6ODB:L3G+
Kasumi-1	M3;xSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHwXFNKSzVyPUCuNFEh\|ryP	M37CfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUO1PVAxLz5{NUWzOVkxODxxYU6=
Kasumi-1/ABT	MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVW0TmhjUUN3ME2wMlUyKM7:TR?=	NVXzcG16RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|U6ODBpPkK1OVM2QTByPD;hQi=>
THP-1	NVS3PHdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3EV5V{UUN3ME2xMlI4KM7:TR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV\|NUmwNEc,OjV3M{W5NFA9N2F-
U937	NFHwOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjZUYVPUUN3ME21MlI6KM7:TR?=	M4nqRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUO1PVAxLz5{NUWzOVkxODxxYU6=
C1498	M1X6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mke1TWM2OD14LkGzJO69VQ>?	NXX0ZmFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|U6ODBpPkK1OVM2QTByPD;hQi=>
RPMI 8226	NIPNfXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXT5doFyUUN3ME2wMlI2KM7:TR?=	Ml\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
MM.1S	NXnJd3ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3G5bGlEPTB;MD60NEDPxE1?	M{LXOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUO1PVAxLz5{NUWzOVkxODxxYU6=
NCI-H929	MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HJfmlEPTB;MUWuNlEh\|ryP	MnPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
U266	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\DTWM2OD1yLk[4JO69VQ>?	Mm\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
MCF-7	M1PUWGNmdGxiVnnhZoltcXS7IFHzd4F6	MVe1JO69VQ>?	NXzre5RjPDhiaB?=	M4HZO2ROW09?	NGC4WGRmdmijbnPld{B1cGVic3Xud4l1cX[rdImgeI8hd3JicnHkbYF1cW:w	NYP5O3VVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NFkyOjRpPkK1OFA6OTJ2PD;hQi=>
MCF-7	M2\PWGFxd3C2b4Ppd{BCe3OjeR?=	Mkj3OUDPxE1?	MVm0M\|I1NzR6IHi=	MoTLSG1UVw>?	MoTXbY5kemWjc3XzJJRp\SClbHXheoVlKFCDUmC=	Mn3UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MEmxNlQoRjJ3NEC5NVI1RC:jPh?=
MCF-7	NEDjWFFHfW6ldHnvckBCe3OjeR?=	M4TZelUh\|ryP	MlOwNlQhcA>?	M1fhbWROW09?	MYHlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO\|aX;uxsA>	MkfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MEmxNlQoRjJ3NEC5NVI1RC:jPh?=
MDA-MB 231	MYXGeY5kfGmxbjDBd5NigQ>?	M37TXFUh\|ryP	NXnmUlBIOjRiaB?=	NUCyNpRkTE2VTx?=	MV\lcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO\|aX;uxsA>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRyOUGyOEc,OjV2MEmxNlQ9N2F-
ZR-75-1	MWPGeY5kfGmxbjDBd5NigQ>?	M1O2XFUh\|ryP	MlGyNlQhcA>?	MluySG1UVw>?	M{HtUoVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>?	MofzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MEmxNlQoRjJ3NEC5NVI1RC:jPh?=
A549	NFf5NGhE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MnL2NE0zOCEQvF2=	Ml[5O\|IhcA>?	MWrEUXNQ	MVrk[YNz\WG\|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN6OEe2Nkc,OjV\|OEi3OlI9N2F-
H1299	NG\LWVBE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	Mk\aNE0zOCEQvF2=	NY\MSZU2PzJiaB?=	MoHDSG1UVw>?	MkfN[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>?	NV7R[VRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFg4PjJpPkK1N\|g5PzZ{PD;hQi=>
HO-8910	MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NITzOZYxNTJyIN88US=>	M3TY[FczKGh?	MV3EUXNQ	NVTmbnJE\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN6OEe2Nkc,OjV\|OEi3OlI9N2F-
HT-29	NVzYT4RWS2WubDDWbYFjcWyrdImgRZN{[Xl?	MYmwMVIxKM7:TR?=	M4\zXVczKGh?	MX;EUXNQ	M4LnboRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN6OEe2Nkc,OjV\|OEi3OlI9N2F-
HCT-116	MXvD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MmDkNE0zOCEQvF2=	MmnCO\|IhcA>?	MoK5SG1UVw>?	NIPvcJFl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw	NVvCSXptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFg4PjJpPkK1N\|g5PzZ{PD;hQi=>
A549	MoD0RZBweHSxc3nzJGF{e2G7	M4H0T\|IxKM7:TR?=	NVXqT2o4PDhiaB?=	MWDEUXNQ	NH21bnZqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XOyaYLpci=>	NVzZ[JV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFg4PjJpPkK1N\|g5PzZ{PD;hQi=>
H1299	M{DlN2Fxd3C2b4Ppd{BCe3OjeR?=	MnXUNlAh\|ryP	MnvaOFghcA>?	MkPUSG1UVw>?	MV7pcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?=	NWjZ[XJCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFg4PjJpPkK1N\|g5PzZ{PD;hQi=>
Sc-1	NHLXUGZE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NVX1S3A4OC5yMECxMVEh\|ryP	MX:5OkBp		MV;k[YNz\WG\|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN5M{WwPEc,OjV\|N{O1NFg9N2F-
OcI-LY18	NYHVWY0xS2WubDDWbYFjcWyrdImgRZN{[Xl?	M1nlNVAvODByMT2xJO69VQ>?	MUC5OkBp		M2HvbIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M3fOT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{ezOVA5Lz5{NUO3N\|UxQDxxYU6=
RL	MlnYR4VtdCCYaXHibYxqfHliQYPzZZk>	MV:wMlAxODFvMTFOwG0>	MoLLPVYhcA>?		NFfpRpVl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MnHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|N{O1NFgoRjJ3M{ezOVA5RC:jPh?=
RKO	MoLqR4VtdCCYaXHibYxqfHliQYPzZZk>	MX6wMVExKM7:TR?=	NHLCXYMzPOLCiXlCpC=>	NFi1fG9FVVOR	M4fOTmlEPTB-4pEJNlXjiIoEtV2=	NYnObZF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFQ{QDNpPkK1N\|A1Ozh\|PD;hQi=>
Caco-2	MkfUR4VtdCCYaXHibYxqfHliQYPzZZk>	NVvrdWQ1OC1zMDFOwG0>	MVmyOQKBkWkEoB?=	MkfUSG1UVw>?	NFPoPGZKSzVyPUG5MlfjiIoEtV2=	NYfJfllDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFQ{QDNpPkK1N\|A1Ozh\|PD;hQi=>
DLD1	M4[5eWNmdGxiVnnhZoltcXS7IFHzd4F6	MorQNE0yOCEQvF2=	NHzL[40zPOLCiXlCpC=>	NXPRboNDTE2VTx?=	M4K5[GlEPTB;MUiuO\|jjiIoEtV2=	MlnCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MESzPFMoRjJ3M{C0N\|g{RC:jPh?=
LS411N	NVPucGQ4S2WubDDWbYFjcWyrdImgRZN{[Xl?	NG\rW\|MxNTFyIN88US=>	MWqyOQKBkWkEoB?=	M4LIU2ROW09?	MYnJR\|UxRTFzLkS35qCKyrWP	MnSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MESzPFMoRjJ3M{C0N\|g{RC:jPh?=
SW620	NUOwS3JmS2WubDDWbYFjcWyrdImgRZN{[Xl?	MVKwMVExKM7:TR?=	M3q4eFI16oDLaNMg	MUHEUXNQ	NV;DU\|dQUUN3ME2xNk4zPOLCidM1US=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyNEO4N{c,OjV\|MESzPFM9N2F-
HCT116	M3nwVmNmdGxiVnnhZoltcXS7IFHzd4F6	M3rB[lAuOTBizszN	NX\ndYE1OjUkgJnoxsA>	MYHEUXNQ	NInBR2RKSzVyPUKwMlQ66oDLwsXN	NGLxfXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwOFM5Oyd-MkWzNFQ{QDN:L3G+
HaCaT	MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NWTaSJVXOC5zL{GvNVAh\|ryP	NYTNeVZ7OjRiaB?=	NVLiN4syTE2VTx?=	NWfyTZd2\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M1jLPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkGwO\|k2Lz5{NUKxNFc6PTxxYU6=
A5-RT3	MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MVqwMlEwOS9zMDFOwG0>	M4fDW\|I1KGh?	MmnjSG1UVw>?	NF\6eoll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NXvPfWc1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNVA4QTVpPkK1NlExPzl3PD;hQi=>
HaCaT	MnLqSpVv[3Srb36gRZN{[Xl?	NHj3bI0yOOLCid88US=>	MmeyNlQwPDhiaB?=	M4nS[WROW09?	NWTPVVI{cW6mdXPld{BOVVBiYX7kJGRPSSCocnHncYVvfGG2aX;u	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJzMEe5OUc,OjV{MUC3PVU9N2F-
A5-RT3	M3rVdWZ2dmO2aX;uJGF{e2G7	NIfCV3YyOOLCid88US=>	NY[zXFNNOjRxNEigbC=>	MYrEUXNQ	M2jWRolv\HWlZYOgUW1RKGGwZDDEUmEh\nKjZ33lcpRifGmxbh?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJzMEe5OUc,OjV{MUC3PVU9N2F-
A5-RT3	MVPGeY5kfGmxbjDBd5NigQ>?	NITwXZk2KM7:TR?=	MmftOkBp	NYC3WVhFTE2VTx?=	Ml;UbY5lfWOnczD0bIUhemWuZXHz[UBw\iCvaYTvZ4hwdmS{aXHsJJBzd3SnaX7zJIFv\CC{ZXT1Z4V{KGOub37v[4VvcWNic4Xyeol3[WxiaX6gZUBk[XOyYYPlMYlv\GWyZX7k[Y51KG2jbn7ldi=>	NYDiephZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNVA4QTVpPkK1NlExPzl3PD;hQi=>
U266	M{fzPGZ2dmO2aX;uJGF{e2G7	MVm1NFAwPzVyIH7N	MV[yOE81QCCq	NIW3ZZVFVVOR	NYDkVmhb\G:5boLl[5Vt[XSnczDCbY0tKHC{aX7jbZBidGy7IITo[UBGVCCrc3;mc5Ju	NWLJW3ZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNFg5QDhpPkK1NlA5QDh6PD;hQi=>
RPMI8226	M{jCUmZ2dmO2aX;uJGF{e2G7	M1Xx[lUxOC95NUCgcm0>	M4nWTVI1NzR6IHi=	NV3UUms4TE2VTx?=	M3z1WYRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyOEi4PEc,OjV{MEi4PFg9N2F-
MM.1S	M1\nfmZ2dmO2aX;uJGF{e2G7	NVTibIFNPTByL{e1NEBvVQ>?	MXuyOE81QCCq	MV7EUXNQ	NG\3fHZld3ewcnXneYxifGW\|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm\|b3\vdo0>	M1vxNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkC4PFg5Lz5{NUKwPFg5QDxxYU6=
Clone A	MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfUOXIxNjMkgKO2NEDPxE1?	M{X0S\|czKGh?	MnLlSG1UVw>?	NFjue29KSzVyPUeuOUDPxE1?	MkHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEi4PFIoRjJ3MkC4PFgzRC:jPh?=
CX-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHhNE4z6oDVNkCg{txO	NFewWHE4OiCq	NXn5bpZGTE2VTx?=	MXLJR\|UxRTFwODFOwG0>	M{XqOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkC4PFgzLz5{NUKwPFg5OjxxYU6=
LS174T	NIn2cY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37GO\|AvOuLCk{[wJO69VQ>?	MVO3NkBp	NHjvUXNFVVOR	M1H4UmlEPTB;MUiuN{DPxE1?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyOEi4Nkc,OjV{MEi4PFI9N2F-
HT29	MnTZRZBweHSxc3nzJGF{e2G7	MnuxNU82NzFyIN88US=>	NGDyNIo1QCCq		NXfvSnJk[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NVOzV4FORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxPVIyQDhpPkK1NVkzOTh6PD;hQi=>
SW480	MXzBdI9xfG:\|aYOgRZN{[Xl?	MmPrNU82NzFyIN88US=>	NH7CNFA1QCCq		M3HUdYNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M1nwd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUmyNVg5Lz5{NUG5NlE5QDxxYU6=
Colo205	M1\VNWFxd3C2b4Ppd{BCe3OjeR?=	M3HkZ\|EwPS9zMDFOwG0>	NVP2SYpyPDhiaB?=		NH3xe3Fk[XW\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NUnFNFdqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxPVIyQDhpPkK1NVkzOTh6PD;hQi=>
Caco2	MWrBdI9xfG:\|aYOgRZN{[Xl?	MmLyNU82NzFyIN88US=>	MXS0PEBp		M1y2S4NifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NGHae2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG5NlE5QCd-MkWxPVIyQDh:L3G+
PCI-13	M2WzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NG[5W\|E4OiCq	MmSxSG1UVw>?	M3nrfWdKPTB;MUWgxtEhOS56IN88US=>	M3TWSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N\|g4Lz5{NUGzPVM5PzxxYU6=
PCI-15B	M3P5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWr3[W03PzJiaB?=	MknpSG1UVw>?	M3X0OWdKPTB;MUGgxtEhPC53IN88US=>	NHXjeYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGzPVM5Pyd-MkWxN\|k{QDd:L3G+
UM-SCC22B	M1HjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4LPeVczKGh?	MVnEUXNQ	MlH0S2k2OD1zOTFCtUAzNjlizszN	NI\VNmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGzPVM5Pyd-MkWxN\|k{QDd:L3G+
UM-SCC47	NWLSOWs4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXW3NkBp	NWrKVIJqTE2VTx?=	NUPpdldHT0l3ME2xPUDDuSBzMj6zJO69VQ>?	NVTJO4FKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxN\|k{QDdpPkK1NVM6Ozh5PD;hQi=>
93-VU-147T	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUG3NkBp	M1XCVmROW09?	M3TNcWdKPTB;ND6zJOKyKDNwNTFOwG0>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF\|OUO4O{c,OjVzM{mzPFc9N2F-
UD-SCC2	NXjXNXdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVXqfXgyPzJiaB?=	NHTwbXpFVVOR	NV3oUI95T0l3ME2yPEDDuSB{Lkmg{txO	Mnm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzM{mzPFcoRjJ3MUO5N\|g4RC:jPh?=
UPCI:SCC90	NVHZ[Zk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV63NkBp	NFHhXo5FVVOR	Mnz3S2k2OD14Lk[gxtEhOS53IN88US=>	M13HW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N\|g4Lz5{NUGzPVM5PzxxYU6=
RPMI-8226	MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NHjsfI8yOjVxMkWwM\|UxOCCwTR?=	Mn;UOFhpyqB?	MXfEUXNQ	NELIRmFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOEKwNkc,OjVyMEiyNFI9N2F-
OPM-2	NHfJeIZE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M4r1dlEzPS9{NUCvOVAxKG6P	M{[3dVQ5cMLi	MlnGSG1UVw>?	MkHZ[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MlHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMEiyNFIoRjJ3MEC4NlAzRC:jPh?=
RPMI-8226	Ml3yRZBweHSxc3nzJGF{e2G7	NGLROYQyOjVxMkWwM\|UxOCCwTR?=	MY[0PIjDqA>?	NVvKT3VnTE2VTx?=	MmTFbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NVjXVIpiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFgzODJpPkK1NFA5OjB{PD;hQi=>
OPM-2	MmDnRZBweHSxc3nzJGF{e2G7	M2fFUVEzPS9{NUCvOVAxKG6P	M3nzT\|Q5cMLi	MoS4SG1UVw>?	MlPMbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M3q5d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC4NlAzLz5{NUCwPFIxOjxxYU6=
COG-LL-319	M1iwOWZ2dmO2aX;uJGF{e2G7	NFSyV2wyODBibl2=	Mm[1NU8{NzZiaB?=	MXLEUXNQ	MVLpcoR2[2W\|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm	NGmzPZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1NVQ4Oid-MkS5OVE1PzJ:L3G+
RS4;11	NXHZWVhjTnWwY4Tpc44hSXO\|YYm=	NUjaNZl5OTByIH7N	NHG4O3AyNzNxNjDo	MlzDSG1UVw>?	NGLnc45qdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JG1kdC1zIHPs[YF3[Wen	NFezPI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1NVQ4Oid-MkS5OVE1PzJ:L3G+
FL5.12	M2LwUmZ2dmO2aX;uJIF{e2G7				NHPmbpRT\X[ncoPhcEBw\iCleYTvb4lv\SC5aYTo[JJif2GuIIDyc5Rm[3Srb36gbY4hUUx\|IHTldIVv\GWwdDDCZ4wzKG:4ZYLlfJBz\XO\|aX7nJI1wfXOnIF\MOU4yOiClZXzsd{BqdiCycnXz[Y5k\SCxZjDic5ZqdmViZ3XsZZRqdixiRVO1NEA:KDBwMEC4JO69VS5?	NGnFUlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
DoHH2	Mln6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NEHpW5FKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIlvKGi3bXHuJGRwUEh{IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGJkdDJiaX6gdJJme2WwY3Wgc4YhOyViRlLTMEBGSzVyIE2gNE4xODh\|IN88UU4>	NWjafWVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUeyOVY5OzRpPkG3NlU3QDN2PD;hQi=>
RS11380	NYmydYNKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NXPi[pVRUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBqdiCqdX3hckBTWzFzM{iwJINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEKlbEKgbY4heHKnc3XuZ4Uhd2ZiMzWgSmJUNCCHQ{WwJF0hOC5yMUSg{txONg>?	NI\hXWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
FL5.12	NXfP[WtKTnWwY4Tpc44h[XO\|YYm=				M2XWPXJmfmW{c3HsJI9nKGO7dH;rbY5mKHerdHjkdoF4[WxicILveIVkfGmxbjDpckBKVDNiZHXw[Y5l\W62IFLjcE15VCCxdnXy[ZhxemW\|c3nu[{Bud3W\|ZTDGUFUvOTJiY3XscJMhcW5icILld4Vv[2Vib3[gZo93cW6nIHflcIF1cW5uIFXDOVAhRSByLkCzJO69VS5?	M2PHc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MkW2PFM1Lz5zN{K1Olg{PDxxYU6=
FL5.12	NFvuVphHfW6ldHnvckBie3OjeR?=				MW\S[ZZmenOjbDDv[kBkgXSxa3nu[UB4cXSqZILhe4FtKHC{b4TlZ5Rqd25iaX6gTWw{KGSncHXu[IVvfCCEY3yyJI93\XKneIDy[ZN{cW6pIH3veZNmKE[ONT6xNkBk\WyuczDpckBxemW\|ZX7j[UBw\iB\|JTDGRnMtKEWFNUCgQUAxNjB3IN88UU4>	NVnQUJRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUeyOVY5OzRpPkG3NlU3QDN2PD;hQi=>
DoHH2	NFjqV4VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M1W1UWlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigbY4hcHWvYX6gSI9JUDJiY3XscJMhd3[ncnX4dJJme3OrbnegRoNtOiCrbjDwdoV{\W6lZTDv[kAyOCViSGOsJGVEPTBiPTCwMlE{KM7:TT6=	M3TRXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MkW2PFM1Lz5zN{K1Olg{PDxxYU6=
RS11380	M2j1UWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MkC1TY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDpckBpfW2jbjDSV\|EyOzhyIHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGJkdDJiaX6gdJJme2WwY3Wgc4YhOTBnIFjTMEBGSzVyIE2gNE4yPSEQvF2u	M3L1TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MkW2PFM1Lz5zN{K1Olg{PDxxYU6=
SUDHL4	MlHVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NEfTeYFKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIlvKGi3bXHuJHNWTEiONDDj[YxteyCxdnXy[ZhxemW\|c3nu[{BD[2x{IHnuJJBz\XOnbnPlJI9nKDNnIF\CV{whTUN3MDC9JFAvOjJizszNMi=>	NH30PJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
FL5.12	NFL2Z2hHfW6ldHnvckBie3OjeR?=				MlOxVoV3\XK\|YXygc4Yh[3m2b3vpcoUhf2m2aHTyZZdidCCycn;0[YN1cW:wIHnuJGlNOyCmZYDlcoRmdnRiQnPsMZhNKG:4ZYLlfJBz\XO\|aX7nJI1wfXOnIF\MOU4yOiClZXzsd{BqdiCycnXz[Y5k\SCxZjCzKUBHSlNuIFXDOVAhRSByLkKyJO69VS5?	NHv4fFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
SUDHL4	Mm\yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NYD0[2FsUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBqdiCqdX3hckBUXUSKTESgZ4VtdHNib4\ldoV5eHKnc4PpcochSmOuMjDpckBxemW\|ZX7j[UBw\iBzMDWgTHMtKEWFNUCgQUAxNjh3IN88UU4>	M4CwV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MkW2PFM1Lz5zN{K1Olg{PDxxYU6=
FL5.12	NWXte3N{S3m2b4TvfIlkcXS7IHHzd4F6		MmLWNlQhcHK\|		NVLobFlOS3m2b4TvfIlkcXS7IHHnZYlve3RiSVyzMYRmeGWwZHXueEBud3W\|ZTDGUFUvOTJiY3XscJMhd3[ncnX4dJJme3OrbnegbJVu[W5iQnPsNkBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjCyOEBpenNiYomgUXRUKGG\|c3H5JIlvKGGkc3XuZ4Uhd2Zic3XyeY0tKEWFNUCgQUAxNjByN{eg{txONg>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDh2MUi4Nkc,OTh6NEG4PFI9N2F-
FL5.12	NGTSZpNEgXSxdH;4bYNqfHliYYPzZZk>		NXvZb\|lHOjRiaILz		MojsR5l1d3SxeHnjbZR6KGGpYXnud5QhUUx\|LXTldIVv\GWwdDDtc5V{\SCITEWuNVIh[2WubIOgc5ZmemW6cILld5NqdmdiaIXtZY4hSmOuLWjMJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEK0JIhzeyCkeTDNWHMh[XO\|YYmgbY4h[WK\|ZX7j[UBw\iC\|ZYL1cUwhTUN3MDC9JFAvODNizszNMi=>	NHzCc5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEi0NVg5Oid-MUi4OFE5QDJ:L3G+
NCI-H146	M3[0cmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M2TtXVQ5KGi{cx?=		M3nYVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMUS2JINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BqdiCycnXz[Y5k\SCxZjCxNEUhcHWvYX6gd4VzfW1uIFXDOVAhRSByLkC4O{DPxE1w	NVTOR5htRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4OFE5QDJpPkG4PFQyQDh{PD;hQi=>
CLL	M3HrTGFxd3C2b4Ppd{Bie3OjeR?=				NF7vZmhKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFPMUEBk\WyuczygSWM2OCB;IECuNFA1PSEQvF2u	NIrlPZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEmyOVQ{Oyd-MkC5NlU1OzN:L3G+
MEF	NGqydmREgXSxdH;4bYNqfHliYYPzZZk>		Ml3RNlQhcHK\|		M1O2ZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJI1kdC1zIHTl[olkcWWwdDDNSWYh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IFPlcIwhfGm2ZYKg[4xwKGG\|c3H5JIlvKHC{ZYPlcoNmKG:oIEGlJJNmenWvLDDFR\|UxKD1iMD6wNFIxOyEQvF2u	NIPOWpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO2OlI6PSd-MkGzOlYzQTV:L3G+
MEF	NXrLVVFMS3m2b4TvfIlkcXS7IHHzd4F6		NUi1PIZCOjRiaILz		NGCyeXREgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBu[2xvMTDk[YZq[2mnboSgUWVHKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDD[YxtKHSrdHXyJIdtdyCjc4PhfUBqdiCycnXz[Y5k\SCxZjCxNEUhe2W{dX2sJGVEPTBiPTCwMlA2OSEQvF2u	MoKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|Nk[yPVUoRjJzM{[2Nlk2RC:jPh?=
MEF	NGDaZ4VEgXSxdH;4bYNqfHliYYPzZZk>		NE\aTmszPCCqcoO=		NGjBXYtEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBu[2xvMTDk[YZq[2mnboSgUWVHKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDD[YxtKHSrdHXyJIdtdyCjc4PhfUBqdiCycnXz[Y5k\SCxZjCxNEUh\mW2YXygZo93cW6nIIPldpVuNCCHQ{WwJF0hOC5yNUGg{txONg>?	M3rGZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{[2Nlk2Lz5{MUO2OlI6PTxxYU6=
RS4:11	MVnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				NH;0WJZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLTOFoyOSClZXzsd{BqdiCycnXz[Y5k\SCxZjCxNEUhcHWvYX6gd4VzfW1uIFXDOVAhRSByLkCyOEDPxE1w	MnX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7Mk[yOFcoRjJ6OUK2NlQ4RC:jPh?=
MOLT4	MmjBRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				NXvwOGNPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xVPCClZXzsd{BqdiCycnXz[Y5k\SCxZjCxNEUhcHWvYX6gd4VzfW1uIFXDOVAhRSByLk[yNkDPxE1w	M3X4UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUK2NlQ4Lz5{OEmyOlI1PzxxYU6=
Jurkat	NFnkNINEgXSxdH;4bYNqfHliYYPzZZk>		Ml63OFghcHK\|		MkPkR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTpVzc2G2IHPlcIx{KGGodHXyJFQ5KGi{czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFnDOVAhRSBzLkO4JO69VS5?	NYnUWXNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFM5PThpPkG5O\|Q{QDV6PD;hQi=>
HCT116	MYDDfZRwfG:6aXPpeJkh[XO\|YYm=		M2rlclQ5KGi{cx?=		NF\SVVdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KGOnbHygeIl1\XJvYnz1[UBie3OjeTygTWM2OCB;IESuNFYh\|ryPLh?=	NFXRPGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0N\|g2QCd-MUm3OFM5PTh:L3G+
SU-8686	MnX6R5l1d3SxeHnjbZR6KGG\|c3H5		M2nhXVQ5KGi{cx?=		NVXLXXJbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW1VvOE[4OkBk\WyuczDh[pRmeiB2ODDodpMh[nliY3XscEB1cXSncj3icJVmKGG\|c3H5MEBKSzVyIE2gOE4zPCEQvF2u	NUKwNoE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFM5PThpPkG5O\|Q{QDV6PD;hQi=>
H460	NEfDNotEgXSxdH;4bYNqfHliYYPzZZk>		NH;5dpE1QCCqcoO=		NXLifVZrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDR4MDDj[YxteyCjZoTldkA1QCCqcoOgZpkh[2WubDD0bZRmei2kbIXlJIF{e2G7LDDJR\|UxKD1iOD6wN{DPxE1w	M33MelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{SzPFU5Lz5zOUe0N\|g2QDxxYU6=
Hepa-1c1c7	M1uxb2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MmPYOFghcHK\|		MofXR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgTIVx[S1zY{HjO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliY3XscEB1cXSncj3icJVmKGG\|c3H5MEBKSzVyIE2gPE43QCEQvF2u	NUjLbmtrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFM5PThpPkG5O\|Q{QDV6PD;hQi=>
MCF7	MmnwR5l1d3SxeHnjbZR6KGG\|c3H5		MlvVOFghcHK\|		NUHIUHZ4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA1QCCqcoOgZpkh[2WubDD0bZRmei2kbIXlJIF{e2G7LDDJR\|UxKD1iMkGuNlYh\|ryPLh?=	NV72OVhWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFM5PThpPkG5O\|Q{QDV6PD;hQi=>
DU145	M4fF[mN6fG:2b4jpZ4l1gSCjc4PhfS=>		NEW4WY81QCCqcoO=		MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC0PEBpenNiYomgZ4VtdCC2aYTldk1jdHWnIHHzd4F6NCCLQ{WwJF0hOjdwNjFOwG0v	NVzFdmJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFM5PThpPkG5O\|Q{QDV6PD;hQi=>
HCT116	NEDESmdEgXSxdH;4bYNqfHliYYPzZZk>		NGLvTYo4OiCqcoO=		NWrKOXJVS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|IHX4dJJme3OrbnegRoNtNXiOLDDCZ4wuOiCjbnSgUYNtNTFiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDR5Lkeg{txONg>?	NIC5bWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG3NlcxOSd-MkKxO\|I4ODF:L3G+
BL21 (DE3)	MlzUSpVv[3Srb36gZZN{[Xl?		M2W3T\|IhcHK\|		NGXXS4dDcW6maX7nJIFn\mmwaYT5JJRwKE5vdHXycYlvfXNiNmigTIl{NXSjZ3fl[EBpfW2jbjDCZ4wzKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEhMESHMzmgZ4VtdHNiYX\0[ZIhOiCqcoOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygTWM2OCB;IECuNFAzKM7:TT6=	M2XESVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NES4PVg5Lz5{MkS0PFk5QDxxYU6=
BL21 (DE3)	MXLGeY5kfGmxbjDhd5NigQ>?		M{i0VVIhcHK\|		NE\hfIhDcW6maX7nJIFn\mmwaYT5JJRwKE5vdHXycYlvfXNiOGigTIl{NXSjZ3fl[EBpfW2jbjDCZ4wugExiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSBqRFWzLUBk\WyuczDh[pRmeiB{IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG\|c3H5MEBKSzVyIE2gNE4xODZizszNMi=>	M1fCfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NES4PVg5Lz5{MkS0PFk5QDxxYU6=
NCI-H146	M1;XRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVK5XlNpPCCmYYnz		M{X0d2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUS2JINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCZU2S4JIF{e2G7LDDJR\|UxKD1iMD6wPVch\|ryPLh?=	Moi3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2NEi5PFgoRjJ{NES4PVg5RC:jPh?=
NCI-H1417	Mn;MS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MUK0JIRigXN?		NILCSVFIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG0NVch[2WubIOgZYZ1\XJiNDDkZZl{KGK7IGfTWFgh[XO\|YYmsJGlEPTBiPTCwMlE{KM7:TT6=	NI\kboI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS0PFk5QCd-MkK0OFg6QDh:L3G+
CCRF-CEM	MoXQR5l1d3SxeHnjbZR6KGG\|c3H5		NFzwTXU1QCCqcoO=		NHXuO5hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBES1KILVPFUUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliY3XscJRqfGW{LXLseYUh[XO\|YYmsJGlEPTBiPTCwMlc1KM7:TT6=	NX7w[nk4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1PFI6QTFpPkKyOVgzQTlzPD;hQi=>
HL60	MXLDfZRwfG:6aXPpeJkh[XO\|YYm=		NELlVJE1QCCqcoO=		NGjQV4dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBk\WyudHn0[ZIu[my3ZTDhd5NigSxiSVO1NEA:KDBwN{[g{txONg>?	NVTJcVJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1PFI6QTFpPkKyOVgzQTlzPD;hQi=>
K562	NHu4S5VEgXSxdH;4bYNqfHliYYPzZZk>		MWS0PEBpenN?		MofwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT\|U3OiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgZ4VtdHSrdHXyMYJtfWViYYPzZZktKEmFNUCgQUA{PC55IN88UU4>	NX:zXlE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1PFI6QTFpPkKyOVgzQTlzPD;hQi=>
NCI-H146	M3vHOGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXLie40yPCCmYYnz		M1vNNWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgyPDZiY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JHdUXDhiYYPzZZktKEmFNUCgQUAxNjB\|NzFOwG0v	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd2N{W5PEc,OjJ5NEe1PVg9N2F-
NCI-H1963	MmrHRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MWW0JIRigXN?		MoHvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFE6PjNiY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JHdUXDhiYYPzZZktKEmFNUCgQUAxNjB3OTFOwG0v	NXTSVZNxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OFc2QThpPkKyO\|Q4PTl6PD;hQi=>
NCI-H1417	NUDrZ5RUSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M{XybFQh\GG7cx?=		MoHWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFE1OTdiY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JHdUXDhiYYPzZZktKEmFNUCgQUAxNjRzMjFOwG0v	NIm4UZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke0O\|U6QCd-MkK3OFc2QTh:L3G+
RS4:11	M3fDOmFxd3C2b4Ppd{Bie3OjeR?=		NIn2WII1QCCqcoO=		NWW2d5k6UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBD[2x{IHTldIVv\GWwdDDoeY1idiCUU{S6NVEh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IFHucoV5cW5iVjDzeIFqdmmwZzDiZZNm\CCobH;3JIN6fG:vZYTyfUwhUUN3MDC9JFAvOjdizszNMi=>	MoHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUSwOVQoRjJ\|M{G0NFU1RC:jPh?=
K562	M3Xu[WFxd3C2b4Ppd{Bie3OjeR?=		NH\qfXM1QCCqcoO=		MkPOTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDNZ4wyKGSncHXu[IVvfCCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFQ5KGi{czDifUBCdm6neHnuJHYhe3SjaX7pcoch[mG\|ZXSg[oxwfyCleYTvcYV1enluIFnDOVAhRSBzNj60JO69VS5?	M3zFTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{G0NFU1Lz5{M{OxOFA2PDxxYU6=
NCI-H1963	M1W4O2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NFHxTmc1KGSjeYO=		NEmye5ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEG5OlMh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgOEBl[Xm\|IHL5JHdUXCCjc4PhfUwhUUN3MDC9JFAvODV2IN88UU4>	M{\Qc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NES4Nlk5Lz5{M{S0PFI6QDxxYU6=
NCI-H187	MVvDfZRwfG:6aXPpeJkh[XO\|YYm=		Ml3rOEBl[Xm\|		MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDF6NzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2IHThfZMh[nliV2PUJIF{e2G7LDDJR\|UxKD1iMD6xN\|c4KM7:TT6=	M3yyNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NES4Nlk5Lz5{M{S0PFI6QDxxYU6=
NCI-H1417	MmDwR5l1d3SxeHnjbZR6KGG\|c3H5		Ml7MOEBl[Xm\|		MkHuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzNEG3JINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IESg[IF6eyCkeTDXV3Qh[XO\|YYmsJGlEPTBiPTCwMlE4OzRizszNMi=>	MlruQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEiyPVgoRjJ\|NES4Nlk5RC:jPh?=
HL60	NFnlbY1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGTiNmc4OiCqcoO=		M1LVfGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvQTdizszNMi=>	MmntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5MUK5N\|koRjJ5N{GyPVM6RC:jPh?=
MCF7	NYi2XoFIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIOxTYw4OiCqcoO=		NFzCRY9Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzPS5\|MzFOwG0v	M2HH[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{GyPVM6Lz5{N{exNlk{QTxxYU6=
U266	NIHicHdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml7HO\|IhcHK\|		M4DYRmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHUzPjZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFI4NjN3IN88UU4>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzdzMkmzPUc,Ojd5MUK5N\|k9N2F-
SKOV3	M4Djd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mk\0O\|IhcHK\|		NXrRUFJwT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uRVkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDR4LkW5JO69VS5?	M13VZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{GyPVM6Lz5{N{exNlk{QTxxYU6=
RS4:11	NWToc41HS3m2b4TvfIlkcXS7IHHzd4F6		M2H2eVI1KGi{cx?=		M4jqZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJUPDpzMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuN\|Mh\|ryPLh?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR3M{GzOUc,Ojl2NUOxN\|U9N2F-
Remb1	NXXuNnpXS3m2b4TvfIlkcXS7IHHzd4F6		MYiyOEBpenN?		MWHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDS[Y1jOSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwNDFOwG0v	NGTUUIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1N\|E{PSd-Mkm0OVMyOzV:L3G+
BL21	M4rGdGZ2dmO2aX;uJIF{e2G7	M3HyVlExKHWP	NHTLWVE{KGi{cx?=		NYj5b41kTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBIOTl4QTDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSClZXzsd{BifCBzMDD1UUBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHPvcZBmfGm2aX;uJIF{e2G7LDDLbUA:KDBwMECxJO69VS5?	NYDucJo2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	NEXFeGxHfW6ldHnvckBie3OjeR?=	NF;iW3UyOCC3TR?=	NI\jXIk{KGi{cx?=		MV\EbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUKjazDjc45rfWejdHXkJJBmeHSrZHWg[pJwdSCJU2SteIFo\2WmIHj1cYFvKEKlbD2yMYxqc2VicILveIVqdiBzIFG5N3YhdXW2YX70JIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKEKOMkGgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOyCqcoOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBkd22yZYTpeIlwdiCjc4PhfUwhU2liPTCwMlAxOTRizszNMi=>	M3r4XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	MoHOSpVv[3Srb36gZZN{[Xl?	MYGxNEB2VQ>?	MoXtN{BpenN?		MoOxSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDZNVk2TiCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvODBzNTFOwG0v	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThyN{WxNkc,OjF6MEe1NVI9N2F-
BL21	M33RUmZ2dmO2aX;uJIF{e2G7	MV2xNEB2VQ>?	NUH2XWRZOyCqcoO=		MkjiSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCZaXzkJJR6eGViQnPsMVIudGmtZTDwdo91\WmwIEGg[ZhxemW\|c3XkJIlvKEW\|Y3jldolkcGmjIHPvcIkhSkx{MTDj[YxteyCjdDCxNEB2VSCjZoTldkA{KGi{czDifUBndHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJINwdXCndHn0bY9vKGG\|c3H5MEBMcSB;IECuNFA{PCEQvF2u	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThyN{WxNkc,OjF6MEe1NVI9N2F-
BL21	MoD4SpVv[3Srb36gZZN{[Xl?	MW[xNEB2VQ>?	NXTJbok{OyCqcoO=		NU[wVoNtTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBGOTJ7SDDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSClZXzsd{BifCBzMDD1UUBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHPvcZBmfGm2aX;uJIF{e2G7LDDLbUA:KDBwMEC0OUDPxE1w	NHrUVJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO\|UyOid-MkG4NFc2OTJ:L3G+
BL21	M1fiUmZ2dmO2aX;uJIF{e2G7	M3O0clExKHWP	MXqzJIhzew>?		NH3WSG5FcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIFLjcE0zNWyra3WgdJJwfGWrbjCxJGU6PkdibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiClb33w[ZRqfGmxbjDhd5NigSxiS3mgQUAxNjByNUig{txONg>?	M{j1bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	NI\rTW5HfW6ldHnvckBie3OjeR?=	MmrsNVAhfU1?	Mkj6N{BpenN?		MlrPSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDBNVQzT2SnbIThNVM3XCCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvODFizszNMi=>	M3zIe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	MW\GeY5kfGmxbjDhd5NigQ>?	NHPLdoEyOCC3TR?=	NEL2NVg{KGi{cx?=		NHX0ZWRFcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIFLjcE0zNWyra3WgdJJwfGWrbjCxJGEyPDKJIH31eIFvfCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iY3;tdIV1cXSrb36gZZN{[XluIFvpJF0hOC5yMkGg{txONg>?	MnnNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	M1TITWZ2dmO2aX;uJIF{e2G7	MoLvNVAhfU1?	MXKzJIhzew>?		NXTMNJV4TGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBNOTNyVjDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSClZXzsd{BifCBzMDD1UUBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHPvcZBmfGm2aX;uJIF{e2G7LDDLbUA:KDBwMEW4JO69VS5?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThyN{WxNkc,OjF6MEe1NVI9N2F-
BL21	NWPOUZBRTnWwY4Tpc44h[XO\|YYm=	NUTXeXpUOTBidV2=	NVm4OWpKOyCqcoO=		MojJSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDk[Yx1[TF\|NmSgcZV1[W62IHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFiY3XscJMh[XRiMUCgeW0h[W[2ZYKgN{BpenNiYomg[ox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDjc41x\XSrdHnvckBie3OjeTygT4khRSByLkC2JO69VS5?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThyN{WxNkc,OjF6MEe1NVI9N2F-
BL21	NGfxNGpHfW6ldHnvckBie3OjeR?=	NF7GPJcyOCC3TR?=	MoH4N{BpenN?		MYHEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUKjazDjc45rfWejdHXkJJBmeHSrZHWg[pJwdSCJU2SteIFo\2WmIHj1cYFvKEKlbD2yMYxqc2VicILveIVqdiBzIFyxN\|BCKG23dHHueEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJINmdGy\|IHH0JFExKHWPIHHmeIVzKDNiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[2:vcHX0bZRqd25iYYPzZZktKEurIE2gNE4xPzNizszNMi=>	NGnkfXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO\|UyOid-MkG4NFc2OTJ:L3G+
BL21	NITYfpdHfW6ldHnvckBie3OjeR?=	MYqxNEB2VQ>?	MnPxN{BpenN?		MnPjSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDSNVAxTSCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvOTZizszNMi=>	M16zU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	MVnGeY5kfGmxbjDhd5NigQ>?	NFSxS4IyOCC3TR?=	MUGzJIhzew>?		NFLlc3dFcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIFLjcE0zNWyra3WgdJJwfGWrbjCxJHYyPDGDIH31eIFvfCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iY3;tdIV1cXSrb36gZZN{[XluIFvpJF0hOC5zOTFOwG0v	NIf4RZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO\|UyOid-MkG4NFc2OTJ:L3G+
BL21	MmTHSpVv[3Srb36gZZN{[Xl?	MUixNEB2VQ>?	MoTRN{BpenN?		M3rJXGRqe3CuYXPlcYVvfCCxZjDCU2RKWFlvQnHrJINwdmq3Z3H0[YQheGWydHnk[UBnem:vIFfTWE11[WepZXSgbJVu[W5iQnPsMVIudGmtZTDwdo91\WmwIEGgRVE1OlRibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiClb33w[ZRqfGmxbjDhd5NigSxiS3mgQUAxNjJ5IN88UU4>	NWrTS3hvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	NXrEOXhGTnWwY4Tpc44h[XO\|YYm=	NXT3SJFFOTBidV2=	MoThN{BpenN?		MlPDSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDMNVMxTyCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvOjlizszNMi=>	NVTJSlgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	M1j3PWZ2dmO2aX;uJIF{e2G7	MVixNEB2VQ>?	NXzOe3RSOyCqcoO=		MULEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUKjazDjc45rfWejdHXkJJBmeHSrZHWg[pJwdSCJU2SteIFo\2WmIHj1cYFvKEKlbD2yMYxqc2VicILveIVqdiBzIF[5O3YhdXW2YX70JIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKEKOMkGgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOyCqcoOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBkd22yZYTpeIlwdiCjc4PhfUwhU2liPTCwMlMh\|ryPLh?=	M3zUelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	NEHCRolHfW6ldHnvckBie3OjeR?=	NHqxZ5UyOCC3TR?=	NX7pPVBHOyCqcoO=		MmPzSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDZNVAyUCCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvOzhizszNMi=>	M1rsc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21 (DE3)	M3u3TmZ2dmO2aX;uJIF{e2G7		NYnJO2NkOiCqcoO=		NIjKUJpDcW6maX7nJIFn\mmwaYT5JJRwKE5vdHXycYlvfXNiNmigTIl{NXSjZ3fl[EBpfW2jbjDCZ4wzKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEhMESHMzmgZ4VtdHNiYX\0[ZIhOiCqcoOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygT4khRSByLkCwNFYh\|ryPLh?=	NYjzNGNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OFg6QDhpPkKyOFQ5QTh6PD;hQi=>
BL21 (DE3)	NIXvbldHfW6ldHnvckBie3OjeR?=		M3LDflIhcHK\|		NVm2c3p[SmmwZHnu[{Bi\m[rbnn0fUB1dyCQLYTldo1qdnW\|IEjYJGhqey22YXfn[YQhcHWvYX6gRoNtNXiOIHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFiKFTFN{kh[2WubIOgZYZ1\XJiMjDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCjc4PhfUwhU2liPTCwMlAxOSEQvF2u	MnXUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2NEi5PFgoRjJ{NES4PVg5RC:jPh?=
Toledo	Ml3DRZBweHSxc3nzJIF{e2G7				M2P4Omlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iVH;s[YRwKGOnbHzzMEBNTDVyIE2gNE4xPiEQvF2u	NHuxdmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY2Oid-MkS5NFA3PTJ:L3G+
KB	NWDzO2VDS3m2b4TvfIlkcXS7IHHzd4F6	NXzTeGE6OC53IIXN			M1rOeWN6fG:2b4jpZ4l1gSCrbjDoeY1idiC\|aWLORU1u\WSrYYTl[E1OS0xzLXvuZ49sKGSxd36gT2Ih[2WubIOgc5ZmemW6cILld5NqdmdiQlPMNkBifCByLkWgeW0>	NFnES3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC0NFA1Oyd-MUiwOFAxPDN:L3G+
Eu-Myc	MYTBdI9xfG:\|aYOgZZN{[Xl?	NIDUO4UyKHWP			MoTpTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDtc5V{\SCHdT3NfYMh[2WubIOgc5ZmemW6cILld5NqdmdiQlPMNkBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINwdG:weTDmc5Ju[XSrb36gZZQhOSC3TR?=	NGDsSXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC0NFA1Oyd-MUiwOFAxPDN:L3G+
HeLa	MkjNSpVv[3Srb36gZZN{[Xl?	NVP2W5JZOSC3TR?=	Mm\LNVIhcHK\|		NFzEcpZKdmS3Y4Tpc44hd2ZiQnPsMZhNNW2nZHnheIVlKGGyb4D0c5NqeyCrbjDkc5h6[3mlbHnuMZN1cW23bHH0[YQhcHWvYX6gTIVN[SClZXzsd{BwfmW{ZYjwdoV{e2mwZzDOc5hiKGG2IEGgeW0h[W[2ZYKgNVIhcHK\|IHL5JGhw\WOqc4Sgd5RicW6rbne=	NYm0T2ZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzPFY6QDJpPkKyN\|g3QTh{PD;hQi=>
HeLa	MW\GeY5kfGmxbjDhd5NigQ>?	NIjG[ZIyOCC3TR?=	MlS3NVYhcHK\|		NWXCNYhxUW6qaXLpeIlwdiCxZjDScJVkNUKjeD;lXWZRNUKlbD34UEBqdnSncnHjeIlwdiCneIDy[ZN{\WRiaX6gbJVu[W5iSHXMZUBk\WyuczDheEAyOCC3TTDh[pRmeiBzNjDodpMh[nliQmLFWEBie3OjeR?=	MljpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2MkWwN\|EoRjJ{NEK1NFMyRC:jPh?=
MDA-MB-231	NGnye45HfW6ldHnvckBie3OjeR?=	M3XUfFAvODNidH:gNUB2VQ>?	MV:xJIhz		NELPWmZCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IILlZ49u[mmwYX70JGJkdC2[TDDhd5Nme3OnZDDhd{Bz\XO2b4LheIlwdiCxZjDCTW0hSkh\|LXnu[JVk\WRiU33hZ{Bxem:2ZXnuJJJmdGWjc3WgbY4hdWm2b3Poc45lemmjIHnzc4xifGWmIH\yc40hVUSDLV3CMVI{OSClZXzsd{BifCByLkCzJJRwKDFidV2gZYZ1\XJiMTDodkBjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	NVjxWFJyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OFc2QThpPkKyO\|Q4PTl6PD;hQi=>
MDA-MB-231	MWTGeY5kfGmxbjDhd5NigQ>?	M2f4VVAvODNidH:gNUB2VQ>?	MUGxJIhz		NWexZ\|R1SW62YXfvcol{fCCjY4Tpeol1gSCjdDDy[YNwdWKrbnHueEBD[2xvWFygZZN{\XO\|ZXSgZZMhemW\|dH;yZZRqd25ib3[gRmlOKEKKMz3pcoR2[2WmIHP5eI9kcHKxbXWgZ{Bz\WynYYPlJIlvKG2rdH;jbI9v\HKrYTDpd49t[XSnZDDmdo9uKE2GQT3NRk0zOzFiY3XscJMh[XRiMD6wN{B1dyBzIIXNJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	Mnm1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5NEe1PVgoRjJ{N{S3OVk5RC:jPh?=
BP3	NWrnV4piSXCxcITvd4l{KGG\|c3H5	NGXoWlAyOCC3TR?=	NG\6S3czPCCqcoO=		NIDjUYJKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFLQN{Bk\WyuczDheEAyOCC3TTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BjgSCDbn7lfIlvKFZiYX7kJJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiRlHDV{Bu\XSqb3S=	NIfWTHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C0O\|IzQCd-MkOwOFczOjh:L3G+
IM9	NYjkRYE6SXCxcITvd4l{KGG\|c3H5	Ml[5NVAhfU1?	NYr5flFPOjRiaILz		M4TXZWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSV25JINmdGy\|IHH0JFExKHWPIHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KEGwbnX4bY4hXiCjbnSgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDiZZNm\CCIQVPTJI1mfGixZB?=	NEDESWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C0O\|IzQCd-MkOwOFczOjh:L3G+
RS4:11	MVTBdI9xfG:\|aYOgZZN{[Xl?	MVixNEB2VQ>?	NVnnW41MOjRiaILz		NX;BOXU6UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDSV\|Q7OTFiY3XscJMh[XRiMUCgeW0hcW6ldXLheIVlKG[xcjCyOEBpenNiYomgRY5v\XirbjDWJIFv\CCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJGZCS1NibXX0bI9l	M3q3O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MES3NlI5Lz5{M{C0O\|IzQDxxYU6=
HCT116	Ml3xRZBweHSxc3nzJIF{e2G7		M{\vUVQ5KGi{cx?=		MW\JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFVEGxOkBxPTNtLzugZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KEGwbnX4bY4hXi2ISWTDJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCvZYToc4Q>	M2LkNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUiyN\|czLz5{Nkm4NlM4OjxxYU6=
DMS53	M4HSdWFxd3C2b4Ppd{Bie3OjeR?=	M1f1fFUhfG9iMUCgeW0>	NVfPPYU{OTJiaILz		MmPmTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCGTWO1N{Bk\WyuczDoZZJjd3KrbnegdFU{KG23dHHueEBie3Onc4Pl[EBieyCleYTvZ4hzd22nIHOgdoVt\WG\|ZTDheEA2KHSxIEGwJJVOKGGodHXyJFEzKGi{czDifUBqdW23bn;icI91fGmwZzDt[ZRpd2R?	MmrsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7OEKzO\|IoRjJ4OUiyN\|czRC:jPh?=
DMS53	NFL2eVVHfW6ldHnvckBie3OjeR?=	NUPxR5piPSC2bzCxNEB2VQ>?	NUnBWYh2OTJiaILz		M2XNWWlvcGmkaYTpc44hd2ZiQlPsMVIwSmmvIHnueIVz[WO2aX;uJIlvKGi3bXHuJGROWzV\|IHPlcIx{KGijcnLvdolv\yCyNUOgcZV1[W62IHH0JFUhfG9iMUCgeW0h[W[2ZYKgNVIhcHK\|IHL5JIludXWwb4Dy[YNqeGm2YYTpc44hdWW2aH;k	M2TNUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUiyN\|czLz5{Nkm4NlM4OjxxYU6=
DMS53	NGXVSnZCeG:ydH;zbZMh[XO\|YYm=	MWq1JJRwKDFyIIXN	NYLidI8zOTJiaILz		M13zXmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iRF3TOVMh[2WubIOgbIFz[m:{aX7nJJA2OyCvdYThcpQh[XO\|ZYPz[YQh[XNiUFHSVEBkdGWjdnHn[UBifCB3IITvJFExKHWPIHHmeIVzKDF{IHjyd{BjgSCrbX31co9jdG:2dHnu[{Bu\XSqb3S=	Mn3iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7OEKzO\|IoRjJ4OUiyN\|czRC:jPh?=
DMS53	NGDNdo9CeG:ydH;zbZMh[XO\|YYm=	NUnrXGZZPSC2bzCxNEB2VQ>?	M36yWFEzKGi{cx?=		NYD6bVE4UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDEUXM2OyClZXzsd{Bp[XKkb4LpcocheDV\|IH31eIFvfCCjc4Pld5Nm\CCjczDjZZNx[XOnLUOgZ4xm[X[jZ3WgZZQhPSC2bzCxNEB2VSCjZoTldkAyOiCqcoOgZpkhcW2vdX7vZoxwfHSrbnegcYV1cG:m	MmTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7OEKzO\|IoRjJ4OUiyN\|czRC:jPh?=
DMS53	NX3vblNxTnWwY4Tpc44h[XO\|YYm=	MoDqOUB1dyBzMDD1US=>	MVixNkBpenN?		M{PJOGlvcGmkaYTpc44hd2ZiQlPsMVIwSmG6IHnueIVz[WO2aX;uJIlvKGi3bXHuJGROWzV\|IHPlcIx{KGijcnLvdolv\yCyNUOgcZV1[W62IHH0JFUhfG9iMUCgeW0h[W[2ZYKgNVIhcHK\|IHL5JIludXWwb4Dy[YNqeGm2YYTpc44hdWW2aH;k	NHfHblI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm4NlM4Oid-Mk[5PFI{PzJ:L3G+
U-2 OS	M3SydZFJXFNiYYPzZZk>				MnzPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	M3\VT5FJXFNiYYPzZZk>				NGD2SmVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	MoD4dWhVWyCjc4PhfS=>				NHLVOlhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	NGXhNmRyUFSVIHHzd4F6				MoDXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?=	Ml;tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	NG\ZU2JyUFSVIHHzd4F6				NELPWYlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	NV\vVnlCeUiWUzDhd5NigQ>?				MonZdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	NES4[3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	M3f2WJFJXFNiYYPzZZk>				MoHVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	NXHSTVI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	NX3Vb3BNeUiWUzDhd5NigQ>?				NESwTYZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	NGHJWow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	MXXxTHRUKGG\|c3H5				MVnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDMRW4uPSClZXzsdy=>	Mk\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	MYrxTHRUKGG\|c3H5				NI\4cGhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBFSU:\IHPlcIx{	MlHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	NUW5XlFmeUiWUzDhd5NigQ>?				NVHHRnY3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	MlrDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	MYHxTHRUKGG\|c3H5				M1vPb5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	NXXtcGJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	M{fjNpFJXFNiYYPzZZk>				MWnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=>	NWmydoZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30	MWfxTHRUKGG\|c3H5				M4HHVJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy\|	MnvpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	NYPxO5dweUiWUzDhd5NigQ>?				NEnSO4NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	NIPPXGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
U-2 OS	NFzPcnVyUFSVIHHzd4F6				NWPiZXpNeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	NEfrUYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	MX3xTHRUKGG\|c3H5				Mki4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=>	NWXa[Y5mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	NGfSWHByUFSVIHHzd4F6				M4[wWZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	NW[3bYxQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	MVfxTHRUKGG\|c3H5				NYi4eph2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	MYDxTHRUKGG\|c3H5				NVXub49ueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	MojTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	M1zCUZFJXFNiYYPzZZk>				NYn0doJOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	NFnwRnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	NFPDRWxyUFSVIHHzd4F6				M{\mNJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	NH\pUnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	MmP5dWhVWyCjc4PhfS=>				M3vPWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DOTZ2MzDj[Yxtew>?	M{f0eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	MUnxTHRUKGG\|c3H5				MnXkdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
TC32	M2XFUJFJXFNiYYPzZZk>				M{DHRZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	MlzqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	M1;le5FJXFNiYYPzZZk>				MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFE5KGOnbHzz	M1GwPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	NFTac4FyUFSVIHHzd4F6				NYD1eHdReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PARP / c-PARP / cleaved caspase 3 ; PubMed: 21393866 J Clin Invest H146 cells were preincubated in normoxia or hypoxia (1% O2) for 18 hours prior to treatment with ABT-737 (89.1 nM ), after which cells were harvested for protein analysis by Western blot. Hif-1a; PubMed: 22006676 Mol Cancer Ther Representative western blots for HIF-1α, PARP and cleaved caspase 3 in response to 24-72 hr exposure to ABT-737 in varying concentration in normoxia and hypoxia in 4 neuroblastoma cell lines. Actin is shown as a loading control. Blots are representative of 3 independent experiments. γ-H2AX / p-ATM; PubMed: 21084274 Cancer Res Induction of γ-H2AX and p-ATM by ABT-737. Cells were treated with 10 µmol/L ABT-737 for 24 hours and then maintained in fresh media for 1 or 2 more days prior to Western blot analysis.	21393866 22006676 21084274
Immunofluorescence	cytochrome C; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the release of mitochondrial cytochrome c (green) into the cytoplasm after ABT-737 exposure (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. Bax; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bax from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field C. To assess whether ABT-737 treatment has an effect on the dimerization of Bax, the levels of dimeric Bax were measured with or without ABT-737 treatment in MC-3 and HN22 cells. Bim; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bim from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. AIF; PubMed: 25034785 Cell Death Differ localization of apoptosis inducing factor (AIF) in LCSC pre-stained with Mitotracker Red and untreated or treated with 500 nM ABT-737 for 48 h. Magnification × 60, zoom × 3, bar 20 μm. p65 ; PubMed: 28846096 Nat Cell Biol BCL-xL dependent SVEC cells were treated with ABT-737 (10 μM) +/- Q-VD-Oph (30 μM) for 1 h, immunostained for p65 and analysed by confocal microscopy. TNF (20 ng/ml) was used as positive control for p65 nuclear translocation. Scale bar represents 30μM. Representative images from three independent experiments.	26447615 25034785 28846096
Growth inhibition assay	Cell viability; PubMed: 22311987 J Biol Chem Stably transfected K562 cells were treated with increasing concentrations of ABT-737, obatoclax, or maritoclax for 24 h. Cell viability was determined by measuring intracellular ATP levels with the CellTiter Glo assay.	22311987
ELISA	IL-6 / IL-8; PubMed: 21084274 Cancer Res The secretion of IL-6 and IL-8 in PV-10 cells treated with DMSO, ABT-737 or enantiomer for 24 hours was determined by ELISA.	21084274

体内研究

ABT-737按30 mg/kg剂量作用于白血病模型，抑制白血病负担值达53% , 且明显延长鼠寿命。ABT-737不会引起血细胞数和血浆化学性质发生变话。^[1] ABT-737延长移植BCL-2传感肿瘤的鼠寿命。^[2] ABT-737按100 mg/kg剂量作用于ATLL鼠模型具有强抗癌活性。^[5]

激酶实验： ^[1]	- 合并荧光偏振实验: 测定GST-BCL-2蛋白家族与FITC-BIM BH3域结合的亲和力。100 nM GST-BCL-2家族融合蛋白和不同浓度 ABT-737在PBS温育2分钟。然后，加入20 nM FITC-BIM BH3 肽。进行荧光偏振，测定IC50值。
细胞实验： ^[4]	- 合并 Cell lines: SCLC细胞系，包括NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR,和DMS114 Concentrations: 0.001-10 μM Incubation Time: 48小时 Method: SCLC细胞在含10%人血浆的 100 μL 组织培养基的96孔培养板上处理48小时，使用MTS测定存活细胞。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 注射ER细胞的Scid 鼠 Dosages: 20 mg/kg和30 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	100 mg/mL (122.93 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2%DMSO+40%PEG300+5%Tween80+53%ddH2O	2mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download ABT-737 SDF

分子量	813.43
化学式	C₄₂H₄₅ClN₆O₅S₂
CAS号	852808-04-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What’s the recommended method about reconstitution of the compound for in vivo animal study?
回答：
For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

选择性强的Bcl-2抑制剂

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
活性最高的Bcl-2抑制剂

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
用于临床的Bcl-2抑制剂

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
最新的Bcl-2家族激活剂

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

研究领域

产品类型

定制您的化合物库

ABT-737

客户使用Selleck生产的ABT-737发表文献313篇：

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download ABT-737 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

相关Bcl-2产品